This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Nuvo Pharmaceuticals Valuation

Q: What is the Fair Price of 23N when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

23N (€0.9) is trading below our estimate of [[fair value]] (€4.81)

Is 23N undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 23N when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 23N (€0.9) is trading below our estimate of fair value (€4.81)

Significantly Below Fair Value: 23N is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 23N?

Key metric: As 23N is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 23N. This is calculated by dividing 23N's market cap by their current earnings.
What is 23N's PE Ratio?
PE Ratio	1x
Earnings	CA$15.17m
Market Cap	CA$15.37m

23N key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.1x
Enterprise Value/EBITDA	4.3x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 23N's PE Ratio compare to its peers?

The above table shows the PE ratio for 23N vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	11.5x
93M1 MPH Health Care	0.8x	-65.7%	€104.5m
PSG PharmaSGP Holding	15.2x	13.6%	€299.8m
DMP Dermapharm Holding	22.6x	17.0%	€2.0b
DIOD DIOD Maker of Eco-Friendly Equipment and Nutrition	7.4x	n/a	₽677.1m
23N Nuvo Pharmaceuticals	1x	n/a	€15.4m

Price-To-Earnings vs Peers: 23N is good value based on its Price-To-Earnings Ratio (1x) compared to the peer average (7.4x).

Price to Earnings Ratio vs Industry

How does 23N's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

2 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	19.7x	21.6%
23N Nuvo Pharmaceuticals	1x	n/a	US$11.21m

2 Companies		Estimated Growth	Market Cap
Industry Avg.	19.7x	21.6%
23N Nuvo Pharmaceuticals	1x	n/a	US$11.21m

No more companies

Price-To-Earnings vs Industry: 23N is good value based on its Price-To-Earnings Ratio (1x) compared to the European Pharmaceuticals industry average (20.9x)

Price to Earnings Ratio vs Fair Ratio

What is 23N's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

23N PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	1x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 23N's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/03/17 13:06
End of Day Share Price	2023/03/16 00:00
Earnings	2022/09/30
Annual Earnings	2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Nuvo Pharmaceuticals Inc. is covered by 6 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
David Martin	Bloom Burton & Co.
Mark Knapp	Clarus Securities Inc.
null null	Eight Capital